KB-707
- Generic Name
- KB-707
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Phase 1
Recruiting
- Conditions
- Lung Cancer, Non-small CellLung Cancer MetastaticSolid Tumor, AdultAdvanced CancerLung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Krystal Biotech, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06228326
- Locations
- 🇺🇸
XCancer Research Network/Dothan Hematology & Oncology, Dothan, Alabama, United States
🇺🇸BRCR Global, Weston, Florida, United States
🇺🇸Ochsner/MD Anderson Cancer Center, New Orleans, Louisiana, United States
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- CancerMelanoma Stage IIIMelanoma Stage IVCutaneous Melanoma
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Krystal Biotech, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT05970497
- Locations
- 🇺🇸
UCLA Health, Los Angeles, California, United States
🇺🇸Mission Dermatology Center, Rancho Santa Margarita, California, United States
🇺🇸BRCR Global, Weston, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath